AAMU
LXRX icon

Amundi Asset Management US’s Lexicon Pharmaceuticals LXRX Stock Holding History

Amundi Asset Management US’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-41,778
Closed -$83K – 1630
2020
Q2 		$83K Hold
41,778
– – ﹤0.01% 1447
2020
Q1 		$81K Buy
+41,778
New +$124K ﹤0.01% 1447

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
UL
Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $66.1B AUM 33.53% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Amundi Asset Management US's LXRX Position: Q3 2020 in Review

Amundi Asset Management US sold out of Lexicon Pharmaceuticals (LXRX) in Q3 2020, closing a stake of 41,778 shares — an estimated $83K sold.

Amundi Asset Management US first reported a position in LXRX in Q1 2020 and held it in 2 quarters. The position peaked at $83K in Q2 2020. 91 funds tracked by Wall St. Rank hold LXRX as of Q3 2020.

  • Amundi Asset Management US reported no remaining Lexicon Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • Amundi Asset Management US sold 41,778 Lexicon Pharmaceuticals shares in Q3 2020, an estimated $83K.
  • Amundi Asset Management US first reported a position in Lexicon Pharmaceuticals in Q1 2020 and held it in 2 quarters.
  • Amundi Asset Management US's Lexicon Pharmaceuticals position peaked at $83K in Q2 2020.
  • 91 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q3 2020.

Based on Amundi Asset Management US's 13F filing for Q3 2020, filed 16 Nov 2020.